Drug intelligence / Profile preview

bortezomib + pemetrexed

Development stage: Unknown
Lead developer: Millennium Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of bortezomib, a proteasome inhibitor, and pemetrexed, an antifolate antineoplastic agent. Bortezomib works by reversibly inhibiting the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells. Pemetrexed inhibits multiple enzymes involved in folate metabolism and DNA synthesis. This combination has been studied primarily for the treatment of non-small-cell lung cancer (NSCLC).

Brand names: Alimta (for pemetrexed)Velcade (for bortezomib)
Other names: pemetrexed disodium + bortezomib

Targets

DHFR (Dihydrofolate reductase)GART (GAR transformylase)PSMB5 (Proteasome subunit beta Type-5)TS (Thymidylate synthase)

Beyond the preview

Go deeper on bortezomib + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bortezomib + pemetrexed.

Explore the full profile